Foli Bio Inc.
June 17, 2025
Company Presentation
Platform for Therapeutics
Foli Bio is pioneering a next-generation transcriptomics and immune profiling platform to advance drug development and precision medicine. We have discovered that exfoliated biological material, such as stool, serves as a rich yet untapped reservoir of biological signals, offering unique insights into human health.
Leveraging our proprietary Foli-seq technology, we have, for the first time, enabled robust, high-sensitivity analysis of the gut transcriptome from ultra-rare human RNA signals in stool. This breakthrough empowers pharmaceutical companies to accelerate drug discovery and development by providing unprecedented, non-invasive insights into gastrointestinal and immune health and transforming precision medicine for immune-related diseases.
Company HQ City:
New York
Company HQ State:
NY
Company HQ Country:
United States
Year Founded:
2023
Lead Product in Development:
Pipeline Development:
• Foli-insights: Ongoing collaborations with pharma and biotech to integrate Foli-seq into drug discovery pipelines.
• Foli-Dx: Ongoing collaborations with academic institutes running IBD clinical trials to develop predictive strategies for drug response to first-line biologic therapies (anti-TNF).
CEO
Yiming Huang
Development Phase of Lead Product
Other/Not Applicable
When you expect your next catalyst update?
Our next catalyst will be the launch of a prospective clinical study with a top academic partner to validate Foli-Dx, our non-invasive diagnostic platform for predicting anti-TNF response in IBD patients. This study will generate key clinical validation data and establish the utility of our platform in personalized treatment strategies.
We are also advancing new Foli-insights partnerships with pharma to integrate Foli-seq into gastrointestinal drug development pipelines. Entering the clinical phase with these partners will represent another major value inflection point for the company.
What is your next catalyst (value inflection) update?
Foli-Dx: July 2026
Foli-insights: December 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}